An 8-day Open-label, Multiple-dose, Multicenter Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age.

Trial Profile

An 8-day Open-label, Multiple-dose, Multicenter Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2013

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 31 Mar 2012 Planned number of patients changed from 36 to 39 as reported by European Clinical Trials Database record.
    • 20 Jun 2011 Safety and preliminary efficacy results presented at the 21st European Meeting on Hypertension.
    • 02 Jun 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top